Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9384923 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2TP53ATM | |
| SCHEMBL16681177 | 0.97 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2TP53ATM | |
| SCHEMBL8460434 | 0.97 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2TP53ATM | |
| SCHEMBL14157639 | 0.97 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2TP53ATM | |
| SCHEMBL2079639 | 0.91 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2TP53TSHR | |
| SCHEMBL989416 | 0.91 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2TP53TSHR | |
| SCHEMBL11859589 | 0.91 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2TP53TSHR | |
| SCHEMBL29058806 | 0.88 | TP53 (0.32) | HCAR2TP53TSHR | |
| Acrylic Acid SCHEMBL28914099 | 0.84 | HCAR2 (0.47) | HCAR2TP53TSHRALDH1A1 | |
| SCHEMBL12496608 | 0.83 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072812-A1 | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones | MICROBIA, INC. (US) | 2007-03-29 | — | — | US | claimed |
| EP-1660456-A2 | QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES | Microbia Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005021495-A2 | QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES | MICROBIA INC. (US) | 2005-03-10 | — | — | WO | claimed |
| EP-2429591-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Cellectar, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8034804-B2 | (Pyrido/thieno)-[f]-oxazepine-5-one derivatives | N.V. ORGANON (NL) | 2011-10-11 | — | — | US | disclosed |
| WO-2010132428-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CELLECTAR, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7566778-B2 | (Pyrido/thieno)-[f]-oxazepine-5-one derivatives | N.V. ORGANON (NL) | 2009-07-28 | — | — | US | disclosed |
| US-20090163473-A1 | (PYRIDO/THIENO)-[f]-OXAZEPINE-5-ONE DERIVATIVES | N.V. ORGANON | 2009-06-25 | — | — | US | disclosed |
| US-7504390-B2 | Benzoxazepine derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2009-03-17 | — | — | US | disclosed |
| EP-1419138-B1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES | ORGANON NV (NL) | 2008-10-29 | — | — | EP | disclosed |
| US-20080262221-A1 | (PYRIDO/THIENO)-[f]-OXAZEPINE-5-ONE DERIVATIVES | N.V. ORGANON (NL) | 2008-10-23 | — | — | US | disclosed |
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | MERCK SHARP & DOHME B.V. (NL) | 2004-09-02 | — | — | US | disclosed |
| EP-1446407-A2 | (PYRIDO/THIENO)-(F)-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR | Akzo Nobel N.V. (NL) | 2004-08-18 | — | — | EP | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| EP-1419138-A1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | Akzo Nobel (NL) | 2004-05-19 | — | — | EP | disclosed |
| EP-1399450-A1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | Akzo Nobel N.V. (NL) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003010132-A1 | N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002102808-A2 | (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR | AKZO NOBEL N.V. (NL) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002100865-A1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| US-3954858-A | Novel sequestrant builders and method of making the same | LEVER BROTHERS COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | CHRNA4, CHRNA10, CHRNA9 | HCAR2 97/4885KEAP1 3929/4885NFE2L2 2285/4885 |
| US-20070072812-A1 | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones | PCSK9, SLC10A1, QDPR | HCAR2 3855/4885KEAP1 135/4885NFE2L2 109/4885 |
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | HCAR2 3508/4885KEAP1 1299/4885NFE2L2 4166/4885 |
| US-20090163473-A1 | (PYRIDO/THIENO)-[f]-OXAZEPINE-5-ONE DERIVATIVES | CHRNA4, CHRNA5, CHRNA6 | HCAR2 160/4885KEAP1 2124/4885NFE2L2 2488/4885 |
| US-20080262221-A1 | (PYRIDO/THIENO)-[f]-OXAZEPINE-5-ONE DERIVATIVES | CHRNA4, CHRNA5, CHRNA6 | HCAR2 180/4885KEAP1 2150/4885NFE2L2 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.